Pfizer Inc. has declared that its experimental antiviral pill for COVID-19 cut rates off hospitalisation and death by nearly 90% in high-risk adults, as the pharmaceutical company joined the race
Pfizer Inc. has declared that its experimental antiviral pill for COVID-19 cut rates off hospitalisation and death by nearly 90% in high-risk adults, as the pharmaceutical company joined the race